

24 January 2018

**To:** Recipients of M100, 28th ed.  
**From:** Jennifer K. Adams, MT(ASCP), MSHA  
Vice President, Standards and Quality  
**Subject:** Correction

This notification is to inform you of corrections made to CLSI document M100, *Performance Standards for Antimicrobial Susceptibility Testing*, 28th ed. The corrections are described below and shown as highlighted and/or stricken text in the table excerpts.

**Table 2A, Zone Diameter and MIC Breakpoints for *Enterobacteriaceae*:**

The dosage regimen provided in Table 2A, comment (7) for ceftazidime-avibactam is listed incorrectly as: “Breakpoints are based on a dosage regimen of 2.5 g (2 g ceftazidime + 0.5 g avibactam) every 8 h over 2 days.”

Table 2A, comment (7) has been corrected to read: “Breakpoints are based on a dosage regimen of 2.5 g (2 g ceftazidime + 0.5 g avibactam) every 8 h over 2 h.”

The Table 2A correction is shown in the table excerpt below.

**Table 2A. Zone Diameter and MIC Breakpoints for *Enterobacteriaceae***

Test/ Report Group	Antimicrobial Agent	Disk Content	Interpretive Categories and Zone Diameter Breakpoints, nearest whole mm				Interpretive Categories and MIC Breakpoints, µg/mL				Comments
			S	SDD	I	R	S	SDD	I	R	
<b>B-LACTAM COMBINATION AGENTS</b>											
B	Amoxicillin- clavulanate	20/10 µg	≥ 18	-	14-17	≤ 13	≤ 8/4	-	16/8	≥ 32/16	
B	Ampicillin- sulbactam	10/10 µg	≥ 15	-	12-14	≤ 11	≤ 8/4	-	16/8	≥ 32/16	
B	Ceftolozane- tazobactam	30/10 µg	≥ 21	-	18-20	≤ 17	≤ 2/4	-	4/4	≥ 8/4	(6) Breakpoints are based on a dosage regimen of 1.5 g every 8 h.
B	Ceftazidime- avibactam	30/20 µg	≥ 21	-	-	≤ 20	≤ 8/4	-	-	≥ 16/4	(7) Breakpoints are based on a dosage regimen of 2.5 g (2 g ceftazidime + 0.5 g avibactam) every 8 h over 2 <b>days</b> .

**Table 2B-1, Zone Diameter and MIC Breakpoints for *Pseudomonas aeruginosa*:**

The dosage regimen provided in Table 2B-1, comment (7) for ceftazidime-avibactam is listed incorrectly as: “Breakpoints are based on a dosage regimen of 2.5 g (2 g ceftazidime + 0.5 g avibactam) every 8 h over 2 days.”

Table 2B-1, comment (7) has been corrected to read: “Breakpoints are based on a dosage regimen of 2.5 g (2 g ceftazidime + 0.5 g avibactam) every 8 h over 2 h.

The Table 2B-1 correction is shown in the table excerpt below.

**Table 2B-1. Zone Diameter and MIC Breakpoints for *Pseudomonas aeruginosa***

Test/ Report Group	Antimicrobial Agent	Disk Content	Interpretive Categories and Zone Diameter Breakpoints, nearest whole mm			Interpretive Categories and MIC Breakpoints, µg/mL			Comments
			S	I	R	S	I	R	
<b>β-LACTAM COMBINATION AGENTS</b>									
A	Piperacillin- tazobactam	100/10 µg	≥ 21	15-20	≤ 14	≤ 16/4	32/4-64/4	≥ 128/4	(6) Breakpoints for piperacillin (alone or with tazobactam) are based on a piperacillin dosage regimen of at least 3 g every 6 h.
B	Ceftazidime- avibactam	30/20 µg	≥ 21	-	≤ 20	≤ 8/4	-	≥ 16/4	(7) Breakpoints are based on a dosage regimen of 2.5 g (2 g ceftazidime + 0.5 g avibactam) every 8 h over 2 <b>days</b> .

If you require any additional clarification regarding these corrections, please contact CLSI Customer Service ([customerservice@clsi.org](mailto:customerservice@clsi.org)).

We appreciate your commitment to CLSI and regret any inconvenience.